Companies › Ashibio
1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Immunology, Other; next expected readout Dec 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Andecaliximab Matrix metalloproteinase 9 inhibitor | MMP9 | Phase 2 | Fibrodysplasia Ossificans Progressiva; Heterotopic Ossification (HO) | Dec 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07024407 | Andecaliximab | Phase 1 | Heterotopic Ossification (HO) | Other | Dec 2028 |
| NCT06508021 | Andecaliximab | Phase 2 | Fibrodysplasia Ossificans Progressiva | Immunology | Feb 2029 |
–
RAPT Therapeutics, Inc., a member of the GSK plc group of companies Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) AnaptysBio Q32 Bio Clarent Biopharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.